rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Philip Hodges

Director

Company insider

Files Form 4 as: Director, Altimmune.

In numbers

Trades disclosed
17
Buys
0
Sells
3
Bought
$0
Sold
$143K
Companies
1
Companies where not an officer
1
First trade
13 Oct 2017
Last trade
1 May 2026
Last filed
1 May 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
ALT AltimmuneDirector · Biotechnology · last 1 May 20260 buys · 3 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 May 2026filed 1 May 2026ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—48,800 at $0.00filing
1 May 2026filed 1 May 2026ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—48,800 at $0.00filing
25 Sep 2025filed 29 Sep 2025ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—48,800 at $0.00filing
26 Sep 2024filed 30 Sep 2024ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—34,900 at $0.00filing
28 Sep 2023filed 29 Sep 2023ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—26,100 at $0.00filing
29 Sep 2022filed 30 Sep 2022ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—23,500 at $0.00filing
23 Sep 2021filed 24 Sep 2021ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—24,100 at $0.00filing
1 Mar 2021filed 1 Mar 2021ALT AltimmuneBiotechnologySEC FORM 4 Sold$96K6,000 at $16.08filing
1 Dec 2020filed 2 Dec 2020ALT AltimmuneBiotechnologySEC FORM 4 Sold$17K1,227 at $13.54filing
30 Nov 2020filed 2 Dec 2020ALT AltimmuneBiotechnologySEC FORM 4 Sold$30K2,500 at $12.00filing
24 Sep 2020filed 16 Oct 2020ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code M—16,850 at $0.00filing
24 Sep 2020filed 16 Oct 2020ALT AltimmuneBiotechnologySEC FORM 4 Code M—16,850 at $0.00filing
24 Sep 2020filed 28 Sep 2020ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—25,500 at $0.00filing
25 Jun 2020filed 29 Jun 2020ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—16,850 at $0.00filing
2 Jan 2019filed 4 Jan 2019ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
17 Oct 2017filed 17 Oct 2017ALT AltimmuneBiotechnologySEC FORM 4 Code J—1,278,471 at $0.00filing
13 Oct 2017filed 17 Oct 2017ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing

News

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026ALT · manilatimes.net · 19 Oct 2026

0 headlines in the last 90 days name Philip Hodges; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care3

Buys in green, sells in red, by the company’s sector.

Related people

Gregory L. WeaverChief Financial Officer · Chief Financial Officer at Altimmune, filing Form 4 there in the last year
Christophe Arbet-EngelsChief Medical Officer · Chief Medical Officer at Altimmune, filing Form 4 there in the last year
Richard Thomas MenziusoPrincipal Accounting Officer · Principal Accounting Officer at Altimmune, filing Form 4 there in the last year
Linda M. RichardsonChief Commercial Officer · Chief Commercial Officer at Altimmune, filing Form 4 there in the last year
Jerome Benedict DursoPresident and CEO · President and CEO at Altimmune, filing Form 4 there in the last year